Investor Presentation Q1 2023

5 Investor presentation First three months of 2023 Sales growth of 25% driven by both operating units Novo NordiskⓇ Reported geographic sales split for first quarter of 2023 Reported therapy area sales and growth for first quarter of 2023 DKK Insulin GLP-1 Other diabetes DKK billion Obesity care Rare disease | Growth at CER North America Operations billion Growth at CER International Operations 41% 60 30 25% 50% -11% 124% -16% 20 20 10 10% International Operations 40 40 18% 10% 52% IO -8% NAO -18% ΙΟ 65% NAO 156% ΙΟ -17% NAO -14% 20 9% -5% 41% 50% 0 0 NAO ΙΟ EMEA China ROW Total 1 GLP-1 Insulin Obesity care Rare disease IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations; CER: Constant exchange rates Note: Unless otherwise specified, sales growth rates are at CER 1'Other diabetes' is included in Total

View entire presentation